Clinical Trials · NCT00560417
Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 339
- Start date
- Nov 2007
- Locations
- 52 sites, United States, Puerto Rico
- Primary endpoint
- Change From Baseline in Hemoglobin A1C (HbA1c) at Endpoint (Last Observation Carried Forward [LOCF])